Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for process/pmg6 returned no results
Showing 2026 to 2040 of 2854 results for process

  1. Intensity modulated radiotherapy for prostate cancer [ID17]

    Discontinued Reference number: GID-TAG396

    Technology appraisal guidance
    Discontinued

  2. Intensity modulated radiotherapy for breast cancer [ID16]

    Discontinued Reference number: GID-TAG390

    Technology appraisal guidance
    Discontinued

  3. Peramivir for treating influenza [ID828]

    Discontinued Reference number: GID-TA10155

    Technology appraisal guidance
    Discontinued

  4. Atrial fibrillation - idraparinux sodium [ID375]

    Discontinued Reference number: GID-TAG383

    Technology appraisal guidance
    Discontinued

  5. AT406 for neoadjuvant treatment of epithelial ovarian cancer [ID1428]

    Discontinued Reference number: GID-TA10809

    Technology appraisal guidance
    Discontinued

  6. Relatlimab with nivolumab for treating advanced malignant melanoma after immunotherapy in people over 12 [ID1612]

    Discontinued Reference number: GID-TA10484

    Technology appraisal guidance
    Discontinued

  7. Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 [ID6385]

    In development Reference number: GID-TA11457 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Levitronix CentriMag for treatment of refractory cardiogenic shock or severe cardiopulmonary insufficiency (discontinued)

    Discontinued Reference number: GID-MT130

    Medical technologies guidance
    Discontinued

  9. Nivolumab with ipilimumab for neoadjuvant treatment of early non-small-cell lung cancer [ID3756]

    Discontinued Reference number: GID-TA10631

    Technology appraisal guidance
    Discontinued

  10. Emphysema - inhaled alpha-1 antitrypsin [ID1200]

    Discontinued Reference number: GID-TA11179

    Technology appraisal guidance
    Discontinued

  11. Eltrombopag for untreated severe aplastic anaemia [ID1198]

    Discontinued Reference number: GID-TA10284

    Technology appraisal guidance
    Discontinued

  12. Masitinib for treating malignant melanoma that has a c-Kit juxtamembrane mutation [ID1082]

    Discontinued Reference number: GID-TA10627

    Technology appraisal guidance
    Discontinued

  13. Listeria monocytogenes vaccine for previously treated malignant pleural mesothelioma ID1353

    Discontinued Reference number: GID-TA10320

    Technology appraisal guidance
    Discontinued

  14. Nintedanib for untreated malignant pleural mesothelioma [ID1424]

    Discontinued Reference number: GID-TA10359

    Technology appraisal guidance
    Discontinued

  15. Savolitinib for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID1638]

    Discontinued Reference number: GID-TA10634

    Technology appraisal guidance
    Discontinued